SCHEMBL23068637

SCHEMBL23068637

CNc1nccc(-c2sc(NC(=O)Nc3ccc(CN4CCCCC4)c(C(F)(F)F)c3)nc2C)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 9/20 0.58
CCNC P24863 6/20 0.58
RET P07949 3/20 0.51
ABL1 P00519 6/20 0.49
NTRK1 P04629 2/20 0.49
TEK Q02763 2/20 0.49
NTRK2 Q16620 2/20 0.49
MAP3K7 O43318 2/20 0.49
MAP4K2 Q12851 2/20 0.49
MAPK14 Q16539 2/20 0.49
MAP3K20 Q9NYL2 2/20 0.49
KDR P35968 2/20 0.47
CDK2 P24941 3/20 0.46
CDK1 P06493 1/20 0.46
SRC P12931 6/20 0.46
CDK9 P50750 2/20 0.44
STK25 O00506 1/20 0.44
CIT O14578 1/20 0.44
MAP2K7 O14733 1/20 0.44
IKBKB O14920 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29629205 1.00 CDK8 (0.58) CDK8CCNCRETABL1NTRK1
SCHEMBL29629218 0.93 CDK8 (0.59) CDK8CCNCRETABL1NTRK1
SCHEMBL29629238 0.93 RET (0.60) CDK8CCNCRETABL1NTRK1
SCHEMBL23068681 0.93 RET (0.60) CDK8CCNCRETABL1NTRK1
SCHEMBL23068646 0.93 CDK8 (0.59) CDK8CCNCRETABL1NTRK1
SCHEMBL23068680 0.93 CDK8 (0.60) CDK8CCNCRETABL1NTRK1
SCHEMBL29629228 0.93 CDK8 (0.60) CDK8CCNCRETABL1NTRK1
SCHEMBL23068652 0.92 CDK9 (0.53) CDK8CCNCRETABL1NTRK1
SCHEMBL23068627 0.92 CDK8 (0.54) CDK8CCNCRETABL1NTRK1
SCHEMBL29629222 0.92 CDK8 (0.54) CDK8CCNCRETABL1NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740484-B1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-09-11 EP disclosed
CN-111757881-B 5- (Pyrimidin-4-yl) thiazol-2-yl urea derivatives as therapeutic agents 澳升医药公司 2024-05-07 CN disclosed
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-03-23 US disclosed
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents AUCENTRA HOLDINGS PTY LTD (AU) 2022-05-10 US disclosed
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents AUCENTRA HOLDINGS PTY LTD (AU) 2022-05-10 US disclosed
US-20210070746-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-03-11 US disclosed
US-20210070746-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-03-11 US disclosed
CN-111757881-A 5- (pyrimidin-4-yl) thiazol-2-ylurea derivatives as therapeutic agents 澳升控股有限公司 2020-10-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS CDK8, CDK18, CDK9 CDK8 1/4885CCNC 38/4885RET 494/4885
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents CDK8, CDK18, CDK9 CDK8 1/4885CCNC 38/4885RET 494/4885
US-20210070746-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS CDK8, CDK18, CDK9 CDK8 1/4885CCNC 38/4885RET 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.